Valérie Clerin
Pfizer (United States)(US)
Publications by Year
Research Areas
Cholesterol and Lipid Metabolism, Electrospun Nanofibers in Biomedical Applications, Cell Adhesion Molecules Research, Tissue Engineering and Regenerative Medicine, Parathyroid Disorders and Treatments
Most-Cited Works
- → LXR ligand lowers LDL cholesterol in primates, is lipid neutral in hamster, and reduces atherosclerosis in mouse(2009)106 cited
- → 2-(4-Chlorobenzyl)-3-hydroxy-7,8,9,10-tetrahydrobenzo[H]quinoline-4-carboxylic Acid (PSI-697): Identification of a Clinical Candidate from the Quinoline Salicylic Acid Series of P-Selectin Antagonists(2006)82 cited
- → Indazole-Based Liver X Receptor (LXR) Modulators with Maintained Atherosclerotic Lesion Reduction Activity but Diminished Stimulation of Hepatic Triglyceride Synthesis(2008)75 cited
- → A zymogen-like factor Xa variant corrects the coagulation defect in hemophilia(2011)71 cited
- → Phosphodiesterase Type 5 Inhibition Reduces Albuminuria in Subjects with Overt Diabetic Nephropathy(2016)65 cited
- → Expression of the cysteine protease legumain in vascular lesions and functional implications in atherogenesis(2008)57 cited
- → Discovery of Phenyl Acetic Acid Substituted Quinolines as Novel Liver X Receptor Agonists for the Treatment of Atherosclerosis(2006)50 cited
- → Tissue Engineering of Arteries by Directed Remodeling of Intact Arterial Segments(2003)47 cited
- → Characterization of the Novel P-Selectin Inhibitor PSI-697 [2-(4-Chlorobenzyl)-3-hydroxy-7,8,9,10-tetrahydrobenzo[h] Quinoline-4-carboxylic acid] in Vitro and in Rodent Models of Vascular Inflammation and Thrombosis(2007)45 cited
- → Discovery of 2-[1-(4-Chlorophenyl)cyclopropyl]-3-hydroxy-8-(trifluoromethyl)quinoline-4-carboxylic Acid (PSI-421), a P-Selectin Inhibitor with Improved Pharmacokinetic Properties and Oral Efficacy in Models of Vascular Injury(2010)40 cited